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Introduction
In the NOVA sodium and potassium analyser*, ion-selective
electrodes measure sodium and potassium by direct potenti-
ometry in separated plasma or serum or in the plasma phase
of whole blood and in urine after dilution. Sodium is
measured using a glass electrode and potassium using a
valinomycin electrode. The sodium, potassium and reference
electrodes all have a straight tube design and these are
connected to a sampling probe, peristaltic pump and reagent
pack via tubing and a pinch valve system. Samples can be
aspirated from sample cups, capillary tubes or syringes. The
sample volume required is 300 tl for blood, plasma or serum,
or 100 ktl for urine.
The NOVA is controlled by a microprocessor which
initiates a two point calibration of the electrodes at 2 hourly
intervals. A single point calibration with an aqueous standard
is automatically carried out with the analysis of each speci-
men and the test result is displayed 58 seconds after the
start of the sample aspiration cycle. The microprocessor also
monitors the performance of the system and if a system
fault is detected this is identified and a fault status code
displayed.
Urine diluent, standards, reference solution and a waste
container, are all supplied in a disposable reagent pack with-
in the instrument. The main operating controls consist of two
push buttons labelled ’calibrate’ and ’analyze’, and auxiliary
controls are also present. These comprise of a series of push
buttons for other functions such as purging the system using
a fast pump speed, testing the system display, displaying out-
put from electrodes in millivolts and setting up the instrument
for analysis in either ’blood’ or ’urine’ mode. The
measurement of sodium and potassium in blood, serum or
plasma is made on an undiluted sample, whereas urine
samples are automatically diluted before analysis with
magnesium acetate solution. After the recommended daily
calibration of the instrument, a sample can be analysed with
the push of a single control button and results are displayed
in approximately one minute.
Materials
Reagents
All reagents required for sample analysis and calibration were
supplied in a fluids pack by NOVA Biomedical. These con-
sisted of a magnesium acetate diluent (52 mmol/1), potassium
chloride reference solution (2 mmol/1), standard solution A
(sodium chloride 140 mmol/1, potassium chloride 4 mmol/1,
magnesium acetate 3 mmol/1) and standard solution B
(sodium chloride 50 mmol/1, potassium chloride 40 mmol/1,
*Manufactured by NOVA Biomedical Newton, Mass, USA, and
marketed in the United Kingdom by American Hospital Supply (UK)
Ltd., Didcot, Oxon.
magnesium acetate 22 mmol!l). In addition NOVA
Biomedical supplied a sodium electrode conditioning fluid
(ammonium bifluoride 100 mmol/1) and four external
standard solutions, with the following compositions:
1. Sodium chloride 150 mmol/1, potassium chloride 6
mmol/1;
2. Sodium chloride 120 mmol/1, potassium chloride 2
mmol/1, magnesium acetate 11 mmol/1;
3. Sodium chloride 100 mmol/1, potassium chloride 100
mmol/1;
4. Sodium chloride 10 mmol/1, potassium chloride 10
mmol/1.
Quality control materials
The following quality control materials were used during the
evaluation and were selected to provide low, medium and
high concentrations of sodium and potassium;
Versatol, Versatol A and Versatol A Alternate (assayed
human control sera) and Quality Assurance Serum II (un-
assayed human control serum) supplied by General
Diagnostics, W. R. Warner & Co. Ltd.; Wellcomtrol and
Wellcome Autoset M (assayed bovine control sera) and Well-
comtrol 2 (assayed horse control serum) supplied by
Wellcome Reagents Ltd.; Equitrol (unassayed horse control
serum) supplied by Tissue Culture Services Ltd.; Preciflo
calibration serum (assayed human control serum) supplied by
Boehringer Corporation Ltd.; Hyland Q-Pak Automated
(assayed human control serum) and Hyland Q-Pak (unassayed
human urine control) supplied by Travenol Laboratories Ltd.;
Fisher and Fisher II (unassayed human urine controls)
supplied by Fisher Scientific Company Diagnostics Division.
Each of the lyophilised quality control materials was
reconstituted according to the manufacturer’s instructions.
Materials used for between batch precision assessment were
dispensed into small plastic tubes and stored at-15C.
Methods
Precision
Within-batch precision was assessed by replicate measure-
ments of a selection of quality control materials (sera and
urines) coveting a range of concentrations of sodium and
potassium and also heparinised whole blood obtained from
hospital patients. Up to 20 measurements were made on each
specimen within as short a time as possible.i
Between-batch precision was assessed by replicate measure-
ments of quality control materials (sera and urines) over a 20
day period. Each day an aliquot of each material was thawed,
mixed and a single measurement made.
Linearity
The linearity of the instrument for sodium and potassium,
in both the blood and urine modes, was assessed by
measurement of a range of aqueous standards and diluted
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quality control materials. This assessment was carried out at
the beginning, middle and end of the six week evaluation
period.
Correlation studies
Plasma sodium and potassium were measured on 26 specimens
from apparently healthy laboratory staff, 159 specimens
from hospital patients and 20 lipaemic specimens from
hospital patients, by the NOVA and by an IL 343 flame
photometer on a Vickers M300 Multichannel Analyser.
Urine sodium and potassium were measured on 100
specimens from hospital patients by the NOVA and by a
Technicon SMA 6/60 flame photometer. Materials from the
Wellcome Group Quality control Programme and the UK
National Quality Control Scheme were analysed by the
Table 1. Precision of NOVA 1 in blood mode, using quality
control sera (n 20 for each material)
Within-batch
Versatol A
Alternate
Quality
Assurance
Serum II
Equitrol
Equitrol
(diluted)
Between-batch
Versatol A
Alternate
Quality
Assurance
Serum II
Equitrol
Equitrol
(diluted)
Sodium
Mean
(mmol/1)
154.3
155.4
142.5
118.9
154.0
154.7
141.7
118.6
SD CV
(mmol/1) (%)
Potassium
Mean SD CV
(mmol/1) (mmol/1) (%)
0.8 0.5 3.13 0.02 0.6
0.4 0.3 7.20 0.05 0.7
0.3 0.2 4.26 0.03 0.6
0.5 0.4 3.56 0.03 0.8
0.7 0.5 3.09 0.03 1.0
0.7 0.5 7.21 0.08 1.2
4.18 0.06 1.4
3.53 0.07 1.9
170-
150-
110-
70
0 0!5 "0
Dilution
Figure 1. Linearity ofNOVA 1 sodium determination in
the blood mode. (X aqueous standards, 0 quality
control serum)
NOVA and the results compared with the flame photo-
meter group mean values.
Each of eight different commercial assayed quality control
materials was analysed in duplicate by both the NOVA and
the IL 343 flame photometer. Results were compared with
the manufacturers’ stated values for sodium and potassium.
A comparison was made between the results from whole
blood measured on the NOVA and those from separated
plasma from the same specimens also measured on the
NOVA 1. The comparison was made on a group of 15
specimens which had been received for blood gas analysis,
and also ,on a group of 21 specimens, collected into lithium
heparin tubes, from apparently healthy laboratory staff.
Statistical methods
Calculation of the means, standard deviations, coefficients of
variation, correlation coefficients and linear regression
analysis were carried out by standard methods using a PDP
11/34 computer.
Comparison of the means was made using either paired or
unpaired Student’s ’t’ test, as appropriate.
Results and discussion
Precision
The within-batch and between-batch precision figures for
control sera for the NOVA operating in the blood mode,
are shown in Table 1. The average coefficients of variation
for sodium were 0.4% (range 0.2 0.5) within-batch and
0.5% (range 0.3 0.6) between-batch. For potassium the
average coefficients of variation were 0.7% (range 0.6 0.8)
within-batch and 1.4% (range 1.0- 1.9) between-batch.
These were considered to be satisfactory.
The within-batch precision data of the NOVA for whole
blood is shown in Table 2. The average within-batch co-
efficient of variation for sodium was 0.3% (range 0.3 0.5)
and for potassium 0.8% (range 0.4.- 1.4). These levels of
precision were also considered to be satisfactory.
The between-batch precision for whole blood could not
be determined because of the unstable nature of the sample
material.
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The within-batch and between-batch precision figures for
the NOVA in the urine mode using urine quality control
materials are shown .in Table 3. The average coefficients of
variation for sodium were 1.2% (range 0.7 1.6) within-
batch and 2.1% (range 1.4 2.7) between-batch. The average
within-batch coefficient of variation for potassium was 1.0%
(range 1.0 1.1) and the average between-batch coefficient
of variation was 2.7% (range 2.0 3.3). The authors consider
the precision of the NOVA for sodium and potassium in
the urine mode to be satisfactory. The greater coefficients of
variation of the instrument in the urine mode as compared to
the blood mode may be due to the additional urine dilution
step.
Linearity
Figures to 4 show the results of linearity experiments. In
each figure a point represents the mean of three measure-
ments made at the beginning, middle and end of the
evaluation period.
Table 2. Within-batch precision of NOVA 1 in blood mode,
using whole blood (The results shown are for n replicate
analyses of each of 10 different whole blood specimens)
Sodium
Mean SD CV
(mmol/1) (mmol/1) (%)
136.6 0.5 0.3
143.1 0.4 0.3
158.8 0.5 0.3
144.5 0.4 0.3
146.3 0.5 0.3
137.0 0.4 0.3
128;9 0.3 0.3
148.7 0.8 0.5
141.3 0.4 0.3
130.9 0.4 0.3
Potassium
Mean
(mmol/1)
4.5’2
4.19
4.26
2.94
2.89
3.52
3.15
3.67
4.32
2.85
CV
(mmol/1) (%)
0.03 0.6’
0.04 0.9
0.03 0.7
0.02 0.5
0.04 1.4
0.02 0.4
0.02 0.8
0.02 0.6
0.04 1.0
0.04 1.3
In the blood mode the NOVA gave linear results for
sodium (Figure 1) and potassium (Figure 2) over the ranges
investigated (50 170 mmol/1 and 8 mmol/1 respectively).
In the urine mode, linear results for sodium were obtained
over the ranges 20 300 mmol/1 for aqueous standards and
50 150 mmol/1 for urine QC material (Figure 3). For
potassium linearity was demonstrated over the ranges 20-
150 mmol/1 for aqueous standards and 20 70 mmol/1 for
urine QC material (Figure 4).
Correlation Studies
a) Patient and normal plasma samples
Table 4 shows the comparison of results obtained by the
NOVA and flame photometry on 26 plasma samples from
apparently healthy laboratory staff (Group 1), 159 plasma
samples from hospital patients (Group 2) and 20 lipaemic
plasma samples from hospital patients (Group 3). In each
group the sodium and potassium results by NOVA are
significantly higher than the corresponding results obtained
by flame photometry. In Group and Group 2 the means
Table 3. Precision of NOVA 1 in urine mode, using urine
quality control specimens (n 20 for each material)
11
11 .Within-ba.t.ch
14 Fisher
9 Hyland Q-Pak 8
8 Fisher II
9 Between-batch 13
16 Hyland Q-Pak
7 Fisher II
Sodium
Mean SD CV
(mmol/1) (mmol/1) (%)
156.5 2.5 1.6
100.2 0.7 0.7
119.9 1.7 1.4
99.7 2.7 2.7
117.6 1.7 1.4
Potassium
Mean SD "CV
(mmol/1) (mmol/1) (%)
70.2 0.8 1.1
38.9 0.4 1.0
49.9 0.5 1.0
38.7 1.3 3.3
49.6 1.0 2.0
o
300
13 100-
"/
0-
0 0’5
Dilution
Figure 3. Linearity ofNOVA 1 sodium determination in
the urine mode. (X= aqueous standards, 0 quality
control urine)
ft.
ft. o
150
100"
+/1
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Figure 4. Linearity ofNOVA 1 potassium determination
in the urine mode. (X aqueous standards, 0 quality
control urine)
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of the differences between results by NOVA and results
by flame photometry were 3.7 mmol/1 for sodium (p<0.01)
and 0.05 mmol/1 for potassium (p<0.01). Similar differences
have been reported by Annan et al [1] and Ladenson [2].
In Group 3 the means of the differences were 4.3 mmol/1
for sodium (p<0.01) and 0.10 mmol/1 for potassium
(p<0.01). The differences found in Group 3 are not signifi-
cantly different from those found in Groups and 2. Figures
5 and 6 show the correlation and linear regression analysis of
the patient data in Group 2 for sodium and potassium
respectively.
b) Patient urine samples
The comparison of results obtained by flame photometry
(SMA 6/60) and the NOVA on 100 urines from hospital
patients is shown in Table 5. Figures 7 and 8 show the
correlation and linear regression analysis for sodium and
potassium respectively. For sodium there is no significant
difference between results obtained by the NOVA and
those by flame photometry.
Analysis of the potassium data shows that the NOVA
values are significantly lower than the flame photometer
results (mean of differences 1.5 mmol/1, p<0.01). All
the urine potassium measurements, which covered a range
of concentrations from 2.7 79.0 mmol/1, were made on
samples which were not diluted before being presented to
the NOVA 1. The NOVA Instruction Manual states that
occasionally urines with potassium values greater than 50
mmol/1 give results 5% to 10% lower than flamephotometry
and that this is attributable to a weak binding agent for
potassium in these samples. Consequently the Instruction
Manual recommends that urines with potassium values
greater than 45 mmol/1 should be diluted in 5 with
distilled water before analysis. The data shown in Figure 8
supports this recommendation.
c) Quality control schemes
Table 6 shows results for sodium and potassium obtained by
the NOVA on materials from the Wellcome and UK
National Quality Control Schemes. The IL flame photometer
160
150-
140-
120-
o.
!
120 130 140 150
IL 343 flame photometer (mmol/I)
160
Figure 5. Comparison of sodium results by flame photo-
meter (IL 343) and NOVA 1 on 159 plasma specimens
from hospital patients. (r O. 95 7, y 0.998x + 4. O)
7"0
@0"
5.o-t
4.04
Z
3.0- ,t
2.0-
2’.0 30 4!0 5TO 60 7.0
IL 343 flame photometer /mmol/I)
Figure 6. Comparison of potassium results by flame
photometer (1L 343)and NOVA 1 on 159 plasma speci-
mens from hospital patients. (r 0.900, y 1.029x-
0.06)
200
,.#. I
100,1 r I
0 50 100 150 200
SMA 6/60 flame photometer (mmol/I)
Figure ?. Comparison of sodium results by flame photo-
meter (SMA 6/60) and NO VA 1 and 1 O0 urine specimens
from hospital patients. (r O. 996, y 1. O12x O. 7)
100 0;
80
I
0 20 40 60 100
SMA 6/60 flame photometer (mmol/I)
Figure 8. Comparison of potassium results by flame
photometer (SMA 6/60) and NOVA 1 on 100 urine
specimens from hospital patients. (r O. 992, y 0.914x +
1.35)
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group mean results from the relevant quality control scheme
are also shown.
In general the NOVA results for potassium show good
agreement with the QC group mean values. Sodium results on
the NOVA results show differences from the flame photo-
meter group mean values which range from-0.1 mmol/1 to
+4.1 mmol/1.
d) Commercial quality control sera
The results shown in Table 7 were obtained from the analysis
of eight commercial quality control materials for sodium and
potassium by NOVA and flame photometry (IL 343).
These results are compared with the manufacturers’ stated
values. Each NOVA and flame photometer result is the
mean of duplicate determinations.
All the control materials were freeze dried preparations
which were reconstituted before use according to the manu-
facturers’ instructions. Versatol, Versatol A, Versatol A
Alternate, Wellcomtrol and Wellcomtrol 2 were recon-
stituted with distilled water. The manufacturer’s diluent for
reconstituting Wellcome Autoset M was an aqueous solution
of sodium bicarbonate; that for Hyland Q-Pak Automated
was a buffer solution containing trimethyl ammonium
bicarbonat and glycerol; and that for Preciflo was an aqueous
solution containing caesium chloride.
The results in Table 7 show that flame photometry
produced sodium and potassium values for the eight QC
materials which were in close agreement with the manu-
facturers’ stated values, but that the NOVA produced
anomalous results for some materials. For Preciflo, the
NOVA gave a sodium result 6.4 mmol/1 lower, and a
potassium result 11.29 mmol/1 higher, than the stated
values. For Hyland Q-Pak Automated, a sodium result
Table 4. Comparison of NOVA 1 and IL 343 flame photo-
meter plasma sodium and potassium determinations
Group 1:26 specimens from apparently healthy laboratory staff.
Group 2:159 specimens from hospital patients.
Group 3:20 lipaemic specimens from hospital patients.
Group 1 (n 26)
NOVA mean (+ SD)
IL 343 mean (+ SD)
Mean of differrences (+ SD)
Group 2 (n 159)
NOVA 1 mean (+ SD)
IL 343 mean (+ SD)
Mean of differences (+ SD)
Group 3 (n 20)
NOVA 1 mean (+ SD)
IL 343 mean (+ SD)
Mean of differences (+ SD)
Sodium (mmol/1)
142.8 (+ 1.8)
139.1 (+ 1.4)
3.7 (+ 1.3)**
139.8(+6.2)
136.1 (+ 6.0)
3.7 (+ 1.8)**
143.8 (+ 4.8)
139.5 (+ 4.8)
4.3 (+ 1.7)**
3.8 mmol/1 lower than the manufacturer’s value was obtained
on the NOVA 1. These anomalies are probably due to inter-
ference with the performance of the electrodes by
components in the reconstituting fluids of these materials.
e) Whole blood and plasma
Table 8 shows the results for sodium and potassium measured
by the NOVA on whole blood compared to the results
obtained on separated plasma from the same specimens. The
data shown is for 15 specimens from hospital patients
(Group 4), and for 21 specimens from apparently healthy
laboratory staff (Group 5). The specimens in Group 4 were
received for blood gas analysis and contained variable
amounts of sodium heparin as anticoagulant. The specimens
in Group 5 were collected into sample tubes containing lithium
heparin. In each group the values of sodium and potassium
on plasma specimens were significantly higher than those
obtained on whole blood. The mean differences between
plasma and whole blood results in Group 4 were 1.3 mmol/1
for sodium (p<0.01) and 0.04 mmol/1 for potassium
(p<0.05). In Group 5 the mean differences were 1.6 mmol/1
for sodium (p<0.01) and 0.04 mmol/1 for potassium
(p<0.01).
The NOVA Instruction Manual states that since the
electrodes do not respond to sodium or potassium in the
cellular components of blood, the instrument will give results
for whole blood which are identical to those obtained on
plasma from the same sample. There are small, but statisti-
cally significant differences, between results obtained on
whole blood and those obtained on separated plasma.
Table 6. Comparison of results by NOVA 1 with IL flame
photometer group means in the Wellcome and UK National
Quality Control Schemes, for sodium and potassium
QC Scheme
Wellcome
National
Potassium (mmol/1) Wellcome
Wellcome
National
4.07 (+ 0.38) Wellcome
4.02 (+ 0.33) National 0.05 (+ 0.09)**
3.98(+0.83)
3.93 (+ 0.80)
0.05 (+ 0.12)**
4.33 (+ 0.76)
4.23 (+ 0.69)
0.10(-+0.13)**
Table 5. Comparison of NOVA 1 and SMA 6/60 flame photo-
meter sodium and potassium determinations in 100 urine
specimens from hospital patients
NOVA 1 mean (+ SD)
SMA 6/60 mean (+ SD)
Mean of differences (+ SD)
NS Not Significant
** p< 0.01
Sodium (mmol]l)
101.2(+50.1)
100.7 (+ 49.3)
0.5 (+ 4.4)NS
Potassiur (mmoi/li
32.0 (-+ 16.0)
33.5(+17.3)
1.5 (+- 2.5)**
Sodium (mmol/1)
NOVA 1
148.8
155.5
123.6
143.4
129.7
154.2
150.6
Group Mean
(SD)
144.7 (2.3)
152.9(2.0)
123.4 (1.9)
140.9(2.1)
128.5 (1.6)
151.8(2.1)
150.6 (2.3)
Potassium (mmol/1)
NOVA
4.51
5.75
3.48
5.19
3.47
5.41
7.10
Group Mean
(SD)
4.43(0.10)
5.70(0.11)
3.49(0.07)
5.10(0.11)
3.47 (0.08)
5.54 (0.12)
7.10(0.19)
Table 7. Comparison of manufacturers’ quoted values for
sodium and potassium in assayed quality control materials
with the means of duplicate determinations for sodium and
potassium b NOVA 1 and IL 343 flame photometer
Material
Versatol
Versatol A
Versatol A
Alternate
Wellcome
Wellcome
Autoset M
Preeiflo
HylandQ-Pak
Automated
Wellcome 2
Sodium (mmol/1)
Manufac- .NOVA IL 343
turer’s 1
value
142 143.6 141.0
129 129.0 128.5
153 152.6 152.0
143 143.6 143.0
147 148.7 147.5
138 131.6 140.0
148 144.2 150.0
149 148.1 149.0
Potassium (mmol/1)
Manufac- NOVA IL 343
turer’s 1
value
5.0 4.95
7.3 7.05
3.1 3.12
4.9 4.81
5.7 5.72
5.1 16.39
5.1 4.85
5.6 5.48
4.95
7.25
3.15
4.90
5.65
5.40
5.00
5.55
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Other ,investigations
a) Probe. position
The NOVA sampling probe has two possible operating
modes, a ’down’ position for aspiration of samples from
specimen cups, and an ’up’ position for aspiration of samples
from syringes or capillary tubes: The two sampling positions
were compared by analysis of two quality control sera
twenty times each in each sampling position. The differences
in the mean sodium and potassium values for each sampling
position were compared and the results, are shown in Table 9.
The sodium values with the probe in the ’up’ position were
significantly higher than those in the ’down’ position.
Specimen showed a difference between the means of 0.7
mmol/1 (p<0.01) and specimen 2 a difference of 0.8 mmol/1
(p<0.01).
For potassium, significantly higher results were also
obtained with the probe in the ’up’ position. For specimen
the difference between the the means (’up’-’down’)
was 0.02 mmol/1 (p<0.05) and for specimen 2 the
difference was 0.03 mmol/1 (p<0.01). The authors are unable
to explain why these differences should exist.
All of the analyses carried out during the evaluation period
were performed with the probe in the ’up’ position with the
exception of the correlation studies performed on Groups
and 2, described earlier.
b) Heparin
The NOVA Instruction Manual recommends that blood
samples be collected with sodium heparin (10-20 units/ml)
as anticoagulant, noting that sodium results will be elevated
by approximately mmol/1. The majority of the measure-
ments on heparinised plasma samples were carded out on
specimens containing lithium heparin but some determin-
ations were also made on samples containing other forms of
heparin. An initial investigation on whole blood samples
collected for blood gas analysis showed some anomalous
results for NOVA sodium and potassium compared to the
flame photometer results. The authors were interested in the
effect of heparin in blood samples collected anaerobically
for blood gas analysis and whether such samples were,suitable
for determination of sodium and potassium by the NOVA 1.
Specimens for blood gas analysis are usually collected into
syringes in which the dead space (needle + syringe end) is
filled with a solution of sodium heparin. Since the dead
space, the concentration of sodium heparin and the volume
of blood collected may all vary, any effects on the measure-
ment of sodium and potassium could also vary.
Table 8. Comparison of results obtained from whole blood
with those from separated plasma from the same specimen,
for sodium and potassium, using the NOVA 1
Group 4:15 specimens from hospital patients. These specimens were
received for blood gas analysis and contained variable amounts of
sodium heparin.
Group 5:21 specimens from apparently healthy laboratory staff.
These specimens were collected into standard 10 ml lithium heparin
tubes.
Group 4 (n 15)
Whole blood mean (+ SD)
Plasma mean (+ SD)
Mean of differences (D)
Group 5 (n 21)
Whole blood mean (+ SD)
Plasma mean (+ SD)
Mean of differences (+ SD)
* p-.0.05
** p/).01
Sodium (mmol/1)
139.9(+8.8)
141.2(+9.1)
1.3 (+ 0.8)**
142.6 (+ 1.7)
144.2 (+ 1.8)
1.6 (+ 0.7)**
Potassium (mmol/1)
3.45 (+ 0.50)
3.49 (+ 0.54)
0.04 (+0.07)*
The effects of sodium heparin (5,000 units/ml heparin,
150 mmol/1 sodium; and 25,000 units/ml heparin, 750
mmol/1 sodium) and calcium heparin (25,000 units/ml)
were investigated by adding 2 ml aliquots of a freshly
collected whole blood specimen to a series of tubes contain-
ing varying amounts of these anticoagulants (from 20 #1 to
200 #1). Table 10 shows results obtained on plasma samples
containing varying amounts and types of heparin.
The main effects are an increase in heparin concentration
which produces a decrease in sodium and potassium values
measured by NOVA 1, and increasing sodium concentration
in the form of 25,000 units/ml s0dium heparin producing an
increase in the sodium values measured by NOVA and flame
photometry, although the increase in the NOVA values are
less than those for flame photometry as a result of the heparin
supressi0n effect.
The type and volume of heparin and the volume of blood
collected should be carefully controlled, otherwise specimens
of blood collected for blood gas analysis may not be suitable
for the determination of sodium and potassium by the
NOVA 1.
General comments
Instrument use
In general, the NOVA is simple to operate and has some
particularly useful features. The results determined on a
specimen are displayed constantly until the next sample is
aspirated, so that if necessary an operator can aspirate a
specimen and IeaVe the instrument. The system of status
codes is useful for identifying possible faults and in addition,
results which may be unreliable (for example, due to the
presence of air in the sample) are presented as a flashing dis-
play.
Instruction manual
The NOVA Instruction Manual is comprehensive and easy
to follow. Included in the manual is a section on problem
solving, which utilises a series of flow diagrams as an aid to
the diagnosis and correction of each fault identified by a
status code. This was found to be particularly useful.
Daily calibration
The Instruction Manual contains a section describing a series
of checks and a calibration procedure to be followed each
day These checks, were performed throughout the evaluation
period and a record was maintained of the values recorded
each day on four external standard solutions. These standards
(two analysed in the blood mode and two in the urine mode)
have limits ascribed to their values, within which results are
considered to be’acceptable.
At the beginning of the evaluation period results on the
external standards were well within these limits, but as the
Table 9. NOVA 1 sodium and potassium results on two
quality control sera
Comparison of "up" and "down" positions of sampling probe.
For each specimen,,n 20 for each probe position.
Specimen
Mean (+ SD) ’up’
Mean (+ SD) ’down’.
Difference (’up’-’down’)
3.99 (+ 0.24) Specimen 2
Mean (+ SD) ’up’
4.03 (+ 0.26)
Mean (+ SD) ’down’
0.04 (+ 0.04)**
Difference (’up’-’down’)
* p<0.05
**p-,0.01
Sodium (mmol/1)
142.3(+0.3)
141.6 (+ 0.4)
0.7**
119.0(+0.5)
118.2(+0.5)
0.8**
Potassium (mmol/1)
4.27 (+ 0.03)
4.25 (+ 0.03)
0.02*
3.56 (+ 0.03)
3.53 (+ 0.02)
0.03**
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level of reagents in the fluid pack approached that at which
replacement was recommended, potassium .results on the
standards analysed in the blood mode fell below the accept-
able limits. Replacement of the fluids pack overcame this
problem.
Instrument faults
The fault status code most commonly displayed referred to
instability of sodium reading, for which the recommended
action is. to treat the electrode with sodium electrode
conditioning fluid. In almost every instance a repeat deter- blood in heparinised syringe)
mination following this treatment gave a satisfactory result. Sodium (mmol/1)
This fault occurred only rarely with urine, plasma or serum Sodium heparin
specimens, but was common when specimens of whole blood (5,000 units/ml NOVA IL 543
were analysed. 150 mmol/1 sodium)
During the evaluation the NOVA was out of action for a a 144.7 140.1
period of four consecutive days, when a fault occurred which b 144.8 139.9
could not be corrected without recourse to American c 144.0 140.9
Hospital Supply Ltd., the United Kingdom distributors of d 139.7 144.3
NOVA 1. In this instance an electronic fault necessitated Sodium heparin
replacement of a circuit board and this could not be identi- (25,000 units/ml
fled by following the problem solving guide in the Instruction
Manual.
Interfering substances
Ladenson [2] has reported that increasing the sodium con-
c.entration from 19 to 171 mmol/1 had no effect on the
potassium values, and that increasing the potassium concen-
tration from 3.5 to 13.1 mmol/1 had no effect on the sodium
/alues. He also reported that no interference was found from
creatinine, uric acid, urea, calcium, lithium and magnesium,
nor from the range of pH values found in plasma.
Some anomalous results were produced by the NOVA
for sodium and potassium determinations in some commercial
quality control materials and it is thought that certain
constituents in the diluents of these materials, for example,
trimethyl ammonium bicarbonate, glycerol or caesium
chloride, interfere with the performance of the electrodes. In
addition, the Instruction Manual states that the use of
standard solutions containing viscosity adjusters and wetting
agents could interfere with the NOVA 1 electrode
performance and that the use of external standards other
than those manufactured by NOVA Biomedical could void
the electrode warranty. The investigation into the effects of
heparin indicates that heparin can also have an effect on the
electrode performance in the NOVA 1, particularly if it is
present in high concentrations.
For the analysis of whole blood, for almost 50% of the
specimens analysed, the NOVA produced an error code
indicating ’instability of sodium reading’. Repeat analysis of
these specimens generally produced satisfactory results. This
problem was not seen when separated plasma or serum
samples were being analysed, nor when urine samples were
being analysed in the urine mode. It was also noted that for
some grossly lipaemic samples, no sodium or potassium results
could be obtained on the NOVA as the instrument con-
tinually produced an error code which represented ’no air
when required’ in the flow path of the instrument.
Conclusions
The NOVA sodium and potassium analyser is simple and
easy to operate. It has the advantage over flame photometry
that gas and a compressed air supply are not required. When
the instrument is left in the ’Star’ mode it is immediately
available for analytical determinations at the touch of a
single ’Analyze’ button.
Table 10. Effect of heparin on sodium and potassium results
determined in plasma from aliquots of a freshly collected
blood sample, by NOVA 1 and IL 543 flame photometer
a. 10 btl heparin per ml blood (equivalent to approximately 10 ml
blood in heparinised syringe)
b. 20//1 heparin per ml blood (equivalent to approximately 5ml blood
in heparinised syringe)
c. 40/21 heparin per ml blood (equivalent to approximately 2.5 ml
blood in heparinised syringe)
d. 100 /.tl heparin per ml blood (equivalent to approximately ml
750 mmol/1 sodium)
a
b
C
d
Calcium heparin
(25,000 units/ml)
a
b
C
d
Potassium (mmol/1)
NOVA
3.84
3.83
3.71
3.56
149.3 148.2 3.64
152.2 157.2 3.37
157.8 176.1 3.03
174.0 223.1 2.45
140.6 137.0 3.77
137.2 135.0 3.72
132.2 132.6 3.53
118.0 122.7 3.05
IL 543
3.74
3.75
3.73
3.85
3.72
3.64
3.58
3.49
3.72
3.78
3.73
3.44
The precision of the instrument both within- and between-
batch is satisfactory. There is, however, a significant
difference between NOVA and flame photometer results
for plasma sodium and potassium and the results confirm
those reported by Ladenson [2]. The differences for potas-
sium are small and possibly not clinically significant. The
differences for sodium, however, are such that results obtained
by NOVA are not directly comparable to those obtained
by flame photometry. These differences cannot be explained
simply on the basis of the lipid and protein content of plasma
and it is recommended that new reference ranges should be
established for plasma sodium determined by NOVA 1.
The diluents of certain commercial quality control
materials contain substances which interfere with the per-
formance of the NOVA electrodes. Heparin in high
concentration can also affect the electrode performance and
unless the heparin concentration in blood gas samples is
carefully controlled then these samples may not be suitable
for sodium and potassium determination by the NOVA 1.
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